Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Makers LaboratoriesBOM:506919 -0.53%66 Net Margin % is 3.06% as of Mar. 2026, which is 9% above its 10-year median of 2.81. GuruFocus rates BOM:506919 with a GF Score™ of 66/100 and a GF Value™ of ₹174.61 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 961 Drug Manufacturers companies, Makers Laboratories ranks worse than 61.91% on this metric.
The historical rank and industry rank for Makers Laboratories's Net Margin % or its related term are showing as below:
BOM:506919'
s Net Margin % Range Over the Past 10 Years
Min: -6.04 Med: 2.81 Max: 6.36
Current: 1.67
BOM:506919's Net Margin % is ranked worse than 61.91% of 961
companies
in the Drug Manufacturers industry
Industry Median: 5.47
vs BOM:506919: 1.67
Makers Laboratories (BOM:506919) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Makers Laboratories Net Margin % Related Terms
Makers Laboratories Net Margin % Historical Data
* Premium members only.
The historical data trend for Makers Laboratories's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Makers Laboratories's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Makers Laboratories Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Makers Laboratories's Net Margin % distribution charts can be found below:
* The bar in red indicates where Makers Laboratories's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Makers Laboratories (BOM:506919) has a Net Margin % of 3.06% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Makers Laboratories and its competitors. This is near median its historical median of 2.81. According to the industry distribution chart, Makers Laboratories ranks #595 out of 961 companies in the Drug Manufacturers industry, placing it in the top 61.9%.
Is Makers Laboratories' Net Margin % too high?
Makers Laboratories' current Net Margin % of 3.06% is near median its 10-year median of 2.81. The Drug Manufacturers industry median Net Margin % is 5.47. Makers Laboratories' value of 3.06% is 44.1% below this industry median. Based on the distribution chart, Makers Laboratories ranks #595 out of 961 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Makers Laboratories has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Makers Laboratories' Net Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Makers Laboratories ranks #595 out of 961 companies for Net Margin %. This places Makers Laboratories in the lower half of its industry. The industry median Net Margin % is 5.47. Makers Laboratories' value of 3.06% is 44.1% below this benchmark. While the company's 10-year median is 2.81 vs. the industry median of 5.47, Makers Laboratories has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.47, based on 961 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Makers Laboratories's current Net Margin % of 3.06% is 44.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Makers Laboratories and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Makers Laboratories's current Net Margin % is 3.06%, which is near median its own 10-year median of 2.81. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Makers Laboratories stock overvalued right now?
Based on GuruFocus' analysis, Makers Laboratories (BOM:506919) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹174.61, compared to a current price of ₹151.50 — trading 13.2% below its estimated fair value. The current Net Margin % is 3.06%, which is near median its 10-year median of 2.81 and 44.1% below the Drug Manufacturers industry median of 5.47. Makers Laboratories' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Makers Laboratories (BOM:506919), the current Net Margin % is 3.06% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Makers Laboratories (BOM:506919) Overvalued in 2026?
Based on GuruFocus' analysis, Makers Laboratories stock appears to be undervalued.
The current stock price of ₹151.50 is trading 13.2% below its estimated GF Value™ of ₹174.61.
GuruFocus considers Makers Laboratories to be Modestly Undervalued.
Key valuation signals for BOM:506919:
Net Margin %: 3.06% (near median its 10-year median of 2.81)
GF Value™: ₹174.61 vs. price of ₹151.50 (13.2% below fair value)
Industry Position: 44.1% below the Drug Manufacturers median (#595 of 961)
No single metric tells the full story. See the BOM:506919 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Makers Laboratories Ltd is an India-based pharmaceutical company. The company is engaged in the manufacturing and marketing of pharmaceutical products. The company's product portfolio includes Duramol (Paracetamol), Artemak-AB, Loroquin (Chloroquine), Nimuwin (Nimuselide), Coffwin (Anti-Cough Range), and Exylin (Amoxycillin range), among others. The reportable segment of the company is the Pharmaceutical segment.
66GF Score
Get the complete analysis for BOM:506919
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:506919 has been successfully added to your 
